Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses

Abstract Background The safety and effectiveness of edoxaban in real‐world clinical settings have not yet been elucidated thoroughly among Japanese patients with nonvalvular atrial fibrillation (NVAF). We report the one‐year interim results of ETNA‐AF‐Japan (Edoxaban Treatment in routiNe clinical pr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Journal of Arrhythmia
Egile Nagusiak: Takeshi Yamashita, Yukihiro Koretsune, Tomoko Nagao, Kazuhito Shiosakai
Formatua: Artikulua
Argitaratua: Wiley 2020-06-01
Gaiak:
Anticoagulants
Atrial fibrillation
DOAC
Edoxaban
Postmarketing surveillance
Sarrera elektronikoa:https://doi.org/10.1002/joa3.12332
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

https://doi.org/10.1002/joa3.12332